LITAF Antikörper
Quick Overview for LITAF Antikörper (ABIN6989826)
Target
Alle LITAF Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Kreuzreaktivität
- Human, Maus
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- Recombinant fusion protein containing a sequence corresponding to amino acids 1-161 of human LITAF (NP_004853.2).
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
WB 1:300-5000
IHC-P 1:200-400
IP(1-2 μg)
IHC() -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C for 12 months.
-
Haltbarkeit
- 12 months
-
-
- LITAF (Lipopolysaccharide-Induced Tumor Necrosis Factor-alpha Factor (LITAF))
-
Andere Bezeichnung
- LITAF
-
Hintergrund
-
Synonyms: LITAF,PIG7,SIMPLE,TP53I7
Background: Lipopolysaccharide is a potent stimulator of monocytes and macrophages, causing secretion of tumor necrosis factor-alpha (TNF-alpha) and other inflammatory mediators. This gene encodes lipopolysaccharide-induced TNF-alpha factor, which is a DNA-binding protein and can mediate the TNF-alpha expression by direct binding to the promoter region of the TNF-alpha gene. The transcription of this gene is induced by tumor suppressor p53 and has been implicated in the p53-induced apoptotic pathway. Mutations in this gene cause Charcot-Marie-Tooth disease type 1C (CMT1C) and may be involved in the carcinogenesis of extramammary Paget's disease (EMPD). Multiple alternatively spliced transcript variants have been found for this gene.
-
Gen-ID
- 9516
-
UniProt
- Q99732
-
Pathways
- Cellular Response to Molecule of Bacterial Origin
Target
-